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Venous thromboembolism (VTE) is prevalent and impactful, with a risk of death, morbidity 3 
and recurrence. Post thrombotic syndrome (PTS) is a common consequence and associated 4 
with impaired quality of life (QoL). 5 
 6 
The ExACT study was a non-blinded, prospective, multi-centred RCT comparing extended 7 
versus limited duration anticoagulation following a first unprovoked VTE (Proximal DVT or 8 
PE). Adults were eligible if they had completed ≥3 months anticoagulation (remaining 9 
anticoagulated). The primary outcome was time to first recurrent VTE from randomisation. 10 
The secondary outcomes included PTS severity, bleeding, QoL and D-dimers. 11 
 12 
281 patients were recruited, randomised and followed up for 24 months (mean age 63, 13 
Male:Female 2:1). There was a significant reduction in recurrent VTE for patients receiving 14 
extended anticoagulation (2.75 vs 13.54 events/100 patient years, aHR 0.20(95%CI:0.09 to 15 
0.46, p<0.001)) with a non-significant increase in major bleeding (3.54 vs 1.18 events/100 16 
patient years, aHR 2.99(95%CI:0.81 to 11.05,p=0.10)). PTS and QoL outcomes were no 17 
different between groups. D-dimer results (on anticoagulation) did not predict VTE 18 
recurrence.  19 
 20 
In conclusion, extended anticoagulation reduced VTE recurrence but did not reduce PTS or 21 
improve QoL and was associated with a non-significant increase in bleeding. Results also 22 
suggest very limited clinical utility of D-dimer testing using a standard cut off on 23 
anticoagulated patients. 24 
 25 
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Introduction  1 
VTE is a prevalent and severe disease with a risk of death, recurrence, psychological impact, 2 
and long-term morbidity resulting from PTS with impaired QoL (Martinez et al 2014, Cohen 3 
et al 2007, Noble et al 2014, Kahn et al 2008, 2016).  4 
 5 
Anticoagulation therapy (AT) remains the mainstay of treatment for VTE. Clinical guidelines 6 
recommend a minimum of 3 months AT for proximal DVT or PE, with consideration of long-7 
term, indefinite duration AT following an unprovoked VTE due to the higher risk of VTE 8 
recurrence than following a provoked VTE (Martinex et al 2014, Baglin et al 2003, NICE CG144, 9 
Kearon et al 2016, Keeling et al 2011). Guidelines also recommend weighing up individual 10 
additional risk factors for recurrence and bleeding with consideration of patient preference 11 
to inform anticoagulation duration decisions. A further consideration is the potential 12 
consequence of recurrence, with a higher risk of death with symptomatic PE than DVT 13 
(Douketis et al 2007) and recurrence as PE more likely if initial presentation was PE (Baglin et 14 
al 2010). Other factors associated with an increased VTE recurrence risk include male sex 15 
(Roach et al 2015), raised D-dimer after cessation of anticoagulation for 1 month (Palareti et 16 
al 2002, Verhovsek et al 2008) and PTS (Rodger et al 2008). Various scores exist to aid 17 
recurrence risk stratification and counselling of individual patients (e.g. DASH, Tosetto et al 18 
2012) but anticoagulation duration decisions are sometimes challenging. 19 
 20 
PTS affects up to 50% of patients following DVT (Kahn et al 2016) and is associated with 21 
significant morbidity and negative impact on QoL. PTS manifests as a spectrum of symptoms 22 
and signs of chronic venous insufficiency in the lower limb including chronic, persistent pain, 23 
swelling, skin changes and leg ulcers. PTS is burdensome and costly due to its prevalence, 24 
severity, and chronicity. At the current time, management remains unsatisfactory and there 25 
is no cure for PTS. In addition, there are no known effective strategies to prevent PTS 26 
following a DVT. Known risk factors for development of PTS include age >65 years, ipsilateral 27 
DVT recurrence and subtherapeutic INR results if on warfarin (>50% of time with 28 
INR<2.0)(Van Dongen et al 2005). Therefore, it is possible that extended duration AT may 29 
reduce risk of PTS by reducing risk of ipsilateral DVT recurrence (including subclinical 30 
recurrence) that may further damage the vascular pump. The 10-year follow-up of the 31 




duration (6 weeks versus 6 months) on risk for PTS in multivariate analysis (Schulman et al 1 
2006). However, there has been no previous studies to test whether extended 2 
anticoagulation duration (beyond 6m) can reduce the risk of PTS.  3 
 4 
The ExACT study was designed to answer whether extended AT for unprovoked VTE, 5 
reduces VTE recurrence and/or the incidence and severity of PTS compared to limited AT. It 6 
also assesses whether extended AT is associated with increased bleeding and improved QoL. 7 
The relationship between VTE recurrence and baseline D-dimer results (all participants 8 
whilst still anticoagulated), and between VTE recurrence and Therapeutic Time in Range 9 
(TTR) for the extended AT group was also explored. 10 
 11 
Methods 12 
Trial design and participants 13 
ExACT was a non-blinded, multi-centre, two-arm, parallel-group RCT. Eligible patients were 14 
aged ≥18 years with a first unprovoked proximal DVT or PE who had completed a minimum 15 
of 3 months AT (target INR 2-3 for those taking warfarin) and remained anticoagulated. 16 
Patients were excluded if they had another indication for long-term AT (e.g. AF), were at high 17 
risk of bleeding (e.g. additional antiplatelet) or very high risk of VTE recurrence (e.g. active 18 
cancer or antiphospholipid syndrome) or a life expectancy <5 years. The full list of exclusion 19 
criteria is available in the protocol (Tullett et al 2013).   20 
 21 
Trial oversight was by a Trial Steering Committee (TSC) and an independent Data Monitoring 22 
Committee (IDMC). Ethics permission was granted by Trent Research Ethics Committee; 23 
reference 11/H0605/5. The trial is registered (ISRCTN:73819751 and EUDRACT:2101-24 
022119-20). 25 
 26 
Recruitment, randomisation and intervention 27 
Patients were identified from UK NHS anticoagulant clinics. Patients who gave informed, 28 




AT. Randomisation was performed within the web-based computerised clinical case report 1 
form. The software used random blocks randomisation (block size of 4) stratified by 2 
diagnosis (DVT or PE). All participants were asked to attend 6 monthly study follow-up clinic 3 
appointments for two years (5 visits in total).  4 
 5 
Blood samples 6 
D-dimers were tested at the baseline appointment (on anticoagulation) on Point of Care 7 
(POC) device (Cobas h 232, Roche Diagnostics). Patient and researcher were blinded to 8 
these results. 9 
 10 
Outcomes 11 
The primary outcome was the time to first recurrent venous thromboembolism (VTE) 12 
between randomisation and 24 months. The secondary outcomes were: measures of 13 
incidence and severity of PTS using the Villalta Scale applied to both legs at baseline and 6 14 
monthly follow-up clinic appointments (Kahn et al 2009), bleeding events (major and 15 
clinically relevant non-major, CRNM) and QoL (VEINES-QOL (22) and EQ-5D-3L)(Khan et al 16 
2006) at 6 monthly follow-up clinic appointments. 17 
 18 
The relationship between VTE recurrence and baseline D-dimer results for all participants, 19 
and between VTE recurrence and Therapeutic Time in Range (TTR) for the extended AT 20 
group was also explored. 21 
 22 
An Independent Adjudication Committee, blind to the intervention allocation, scrutinised all 23 
thrombotic and haemorrhagic events in order to obtain objective confirmation.    24 
 25 
Statistical analysis 26 




The study was designed to compare 2-year VTE recurrence rates between participants in the 1 
extended versus discontinued AT arms, and also to compare these rates for a group of 2 
participants with a baseline raised D-dimer (Palareti et al 2002). A sample size of 352 (176 per 3 
arm) would be sufficient to detect a clinically important difference between the arms with 4 
minimum 86% power, two-sided alpha=0.05, assuming recurrence rates between 1.4% and 5 
4.3% for the extended AT arm and 14.2% in the discontinued AT arm (Prandoni et al 2007). 6 
Recruitment was lower than expected and at the TSC request, the power calculation was re-7 
estimated where it was determined that a sample of 270 participants (allowing for 10% loss 8 
to follow up) would provide at least 80% power to detect the planned effect sizes. 9 
 10 
Analysis 11 
All primary analyses (primary and secondary outcomes) were performed on an intention to 12 
treat basis (ITT). 13 
 14 
Participant characteristics are summarised by treatment arm using descriptive statistics.  15 
 16 
The number and percentage of participants with at least one recurrent VTE is presented by 17 
trial arm. Cox regression analysis was used to compare the time to first recurrent VTE between 18 
randomisation arms, censoring for deaths, losses to follow-up and withdrawals of consent to 19 
use data. The analysis was adjusted for diagnosis (DVT/PE) at baseline.  The proportional 20 
hazards assumption was tested by cumulative log hazard plots and including a time by 21 
treatment covariate in the analysis. The treatment effect is presented as a hazard ratio, with 22 
the total number of events and the number of events per 100 patient years to aid 23 
interpretation of the data.  24 
 25 
Analysis to compare the time to the first major and CRNM bleeding events (as separate 26 
outcomes) between randomisation arms was performed as per the primary outcome. 27 
 28 
Repeated measures mixed modelling was used to compare the PTS score between arms over 29 




12, 18 and 24 months, including an interaction term between treatment and time point. The 1 
worst score from both of the participant’s legs was counted as the score for the participant. 2 
The model was adjusted for the baseline PTS score; assessment time and diagnosis (DVT/PE) 3 
at baseline were included as fixed effects. Model assumptions were checked for evidence of 4 
non-normality in the residuals. The adjusted mean PTS scores at each time point are 5 
presented by arm. The presence and severity of PTS is also reported, using frequencies and 6 
percentages, according to the following cut offs (0-4:no PTS, 5-9:mild PTS, 10-14:moderate 7 
PTS, ≥15:severe PTS). 8 
 9 
Estimates of treatment effects are presented with 95%, two-sided confidence intervals and P 10 
values.  11 
 12 
Subgroup analyses were limited to primary outcome (time to first VTE recurrence) and main 13 
secondary outcome (time to first major bleeding event) and the predefined subgroups sex 14 
and age (≤65, >65years). Each subgroup effect was independently assessed by the inclusion 15 
of a treatment arm by subgroup interaction term in the Cox model. Subgroup related 16 
estimates and 95% confidence intervals are presented with interaction results alongside. 17 
 18 
VTE recurrence rates are summarised by baseline D-Dimer level (<0.5µg/ml and ≥ 0.5µg/ml) 19 
for all participants.  TTR results are summarised for participants on warfarin in the extended 20 
AT group by whether or not a VTE recurrence occurred during follow-up.  21 
 22 








 Figures 1A and 1B summarise the flow of patients from initial screening through 1 
recruitment, randomisation and follow up. Two hundred and eighty-one patients provided 2 
written informed consent to participate and were randomised between July 2011 and 3 
February 2015 (141 to the extended AT and 140 to discontinued AT). In the extended AT 4 
arm, only 2 patients continued on rivaroxaban and the others (n=139) remained on 5 
warfarin. All 281 trial participants attended visit 1, 273/281 (97%) attended visit 2, 263 6 
(94%) attended visit 3 and 260/281 (93%) visit 4.  7 
 8 
Six participants in the discontinued AT group (4 withdrawals, 1 protein S deficiency and 1 9 
antithrombin deficiency) and two in the extended AT group (1 withdrawal and 1 10 
antiphospholipid syndrome) were excluded from the final ITT analysis by post-randomisation 11 
pre-defined exclusions. 12 
 13 
Baseline Characteristics 14 
No differences were found in baseline characteristics (Table 1). The mean age of participants 15 
was 63, with a roughly even split between DVT and PE, whilst 67% of participants were male. 16 
Primary outcome 17 
Over 24 months follow up, there were 32 recurrent VTEs in 31 patients (13.54 events/100 18 
patient years, PY) within the discontinued AT group versus 7 events in 7 patients (2.75 19 
events/100PY) in the extended AT group (aHR=0.20,95% CI:0.09 to 0.46, p<0.001)(Table 2A, 20 
Figure 2A). In this study, there is no evidence that sex or age group had a differential effect 21 
on the risk of VTE recurrence (p=0.099 and p=0.267 respectively Table 2B).  22 
Secondary outcomes 23 
There were 3 major bleeding events (1.18/100PY) in the discontinued AT group versus 9 24 
(3.54/100PY) in the extended anticoagulation group (aHR=2.99,95%CI: 0.81 to 11.05, p=0.10). 25 
There were 19 clinically relevant non-major bleeding (CRNM) events (8.13/100PY) in the 26 
discontinued AT group, and 28(12.50/100PY) in the extended AT group (aHR=1.51,95%CI: 27 
0.84 to 2.71, p=0.165). These differences were not statistically significant (Table 2A, Figure 28 
2B and C). In this study, there is no evidence that sex or age group had a differential effect on 29 





D-dimers were tested at baseline in 273 patients and only 12 patients (4.4%) had D Dimer≥0.5 2 
µg/ml and of these, 3 patients had recurrent VTE and 9 did not. A higher percentage of those 3 
with VTE recurrence had a baseline D-dimer≥ 0.5µg/ml (n=3 of 38, 7.89% vs n=9 of 235, 3.83%) 4 
but this was not statistically significant (Table 3A). 5 
 6 
Similarly, time in therapeutic range (TTR) for patients on extended AT with warfarin was not 7 
significantly different between those with or without recurrence but the number of 8 
recurrences were small (Table 3B). Patients randomised to warfarin overall had a mean time 9 
in therapeutic range (TTR) of 77% (recurrent VTE TTR=84% vs no recurrence=76%). 10 
 11 
Outcome measures of QoL and PTS were not different between the groups (Table 4A). An 12 
additional post-hoc analysis of patients only presenting with DVT at baseline, also showed no 13 




The ExACT study adds to accumulating evidence that extended AT reduces risk of VTE 18 
recurrence in patients with a first unprovoked VTE but also adds new perspective by assessing 19 
the additional clinically relevant outcomes of PTS and QoL. ExACT also explores the value of 20 
D-dimer testing on anticoagulated patients to predict VTE recurrence. 21 
 22 
A recent Health Technology Assessment (Sterne et al 2017) reviewed all RCTs for VTE 23 
secondary prevention and found 10 multicentre phase III trials (total n=10,390 participants). 24 
Four studies evaluated therapeutic warfarin for varying durations beyond 3 months versus no 25 
anticoagulation (Campbell et al  2007, Agnelli et al 2001, Agnelli et al 2003, Kearon et al 1999), 26 
two evaluated aspirin (Beccattini et al 2012, Brighton et al 2012) and four evaluated direct 27 
oral anticoagulants (DOACs) (Agnelli et al 2013, Wells et al 2016, Romualdi et al 2011, 28 
Bauersachs et al 2010, Schulman et al 2013, Weitz et al 2017). All currently licensed DOACs 29 
for this indication (Apixaban, Rivaroxaban and Dabigatran) have been compared to placebo. 30 




warfarin. In addition, Rivaroxaban and Apixaban have been tested at lower “prophylactic 1 
doses” for VTE secondary prevention.  2 
 3 
Taken together, the published evidence demonstrates that extended AT (warfarin or DOAC) 4 
beyond 3 months significantly reduces VTE recurrence but only whilst on anticoagulation and 5 
balanced against this is an increased risk of bleeding. Compared to Warfarin, Dabigatran was 6 
non-inferior in efficacy but with less major or CRNM bleeding events in the dabigatran arm. 7 
Compared to placebo, Dabigatran, Rivaroxaban and Apixaban all reduced the risk of VTE 8 
recurrence but resulted in increased bleeding, apart from the lower dose of apixaban 2.5mg 9 
bd which had equivalent bleeding risk to placebo. Compared to aspirin, rivaroxaban was more 10 
effective with equivalent bleeding risk.  11 
 12 
The ExACT study is in alignment with this literature, demonstrating an 80% reduction in VTE 13 
recurrence risk for patients receiving extended AT following an unprovoked VTE. There were 14 
numerically more bleeding events in the extended AT arm, but not a statistically significant 15 
difference, likely due to the small number of events. Interpretation of subgroup analyses in 16 
the ExACT trial (age and sex) is also limited due to insufficient patient numbers (including only 17 
1/3 female) and infrequent events. For example, the 3 fold increase in major bleeding events 18 
in >65 years patients on extended AT aligns with previous literature, but the small number of 19 
events meant statistical significance was not reached.  20 
 21 
The TTR for the ExACT study was 77% which compares favourably with warfarin secondary 22 
prevention clinical trials (mean TTR: 64% in LAFIT, 65.3% in RE-MEDY and 81% in WODIT-DVT). 23 
Subtherapeutic INR has been associated with risk of VTE recurrence in previous studies 24 
(Nordstrom et al 2015) but in ExACT, the few recurrences that occurred on extended AT did 25 
not appear related to poor INR control (mean TTR=84% in those with VTE recurrence vs 76%). 26 
 27 
Remarkably, none of the published 10 RCTs for VTE secondary prevention have included 28 
measurement of PTS as an outcome and as this is the greatest source of morbidity and 29 
impaired quality of life following a DVT, the inclusion of this assessment in the ExACT study is 30 
important and novel. Currently, there are no effective PTS prevention interventions that are 31 




reduced risk of PTS with catheter directed thrombolysis for proximal DVT (Haig et al 2016), 1 
the ATTRACT study failed to demonstrate benefit (Vedantham 2017). In addition, the 2 
consistently reported increased bleeding risk and need for interventional radiology makes this 3 
intervention only applicable to a minority of patients. Compression stockings were long 4 
thought to reduce risk of PTS following DVT and were routinely used. However, recent data 5 
including large placebo controlled RCT have failed to demonstrate benefit of compression 6 
stockings to reduce risk of PTS following DVT(Subbiah et al 2016).  7 
 8 
The ExACT study is the first to evaluate whether extended AT could reduce the incidence of 9 
PTS.  It has previously been reported that the majority of patients with a PE diagnosis have an 10 
associated DVT (approximately 70%, Wilbur and Shian 2017), but it is not standard practice 11 
to screen and diagnose these as findings do not influence management. Consistent with this, 12 
patients recruited to the ExACT study with a PE were not routinely screened for DVT but PTS 13 
assessments were done for all patients (DVT and PE). By 2 years follow up, although over half 14 
of patients had developed some degree of PTS, only a minority of these were severe and there 15 
were no differences in frequency or severity between those patients randomised to extended 16 
versus discontinued AT. A post-hoc restricted analysis of patients only presenting with DVT 17 
also showed no evidence of a difference in PTS outcomes between groups. Previous data 18 
demonstrated that subtherapeutic INRs in the initial phase of AT is a risk factor for PTS (van 19 
Dongen et al 2005), which when combined with ExACT results, suggests optimising initial 20 
anticoagulation treatment is the priority to reduce PTS risk rather than extending the 21 
duration. It also suggests that the pathogenesis of PTS results from venous damage associated 22 
with the initial acute event rather than any ongoing further new thrombotic process. In 23 
addition, extending AT did not show evidence of an improved QoL as assessed by either 24 
generic or disease specific measures of QoL.  25 
 26 
To-date, numerous clinical studies have evaluated D-dimer assays as a predictive biomarker 27 
for VTE recurrence but most studies have tested D-dimers after discontinuation of 28 
anticoagulation for 1 month. Raised D-dimers at this time point have been associated with a 29 
higher risk of VTE recurrence (Verhovsek et al 2008, Palareti et al 2002). However, stopping 30 
anticoagulation for 1 month to enable testing is logistically complex and potentially harmful 31 





Kearon et al assessed D-dimer testing to select patients with a first unprovoked venous 2 
thromboembolism who can stop anticoagulant therapy in a cohort study (n=410). By far the 3 
majority (97%) of anticoagulated patients had a negative D-dimer. Of these, 85% continued 4 
to have negative D Dimers after stopping anticoagulation for 1 month but still remained at 5 
high risk of recurrent VTE (annual recurrence of 9.7% men and 5.4% women)(Kearon et al 6 
2015).   This highlights the reduced sensitivity of D-dimer testing in anticoagulated patients 7 
and the limitations of D-dimer testing to decide which patients can safely stop 8 
anticoagulation. Kearon et al have recently published an updated analysis of this cohort with 9 
extended follow up (median of 5 years) and demonstrated a continued high risk of VTE 10 
recurrence in male patients with a negative D-dimer (testing off anticoagulation, 11 
7.5%/PY)(Kearon et al 2019).  Similarly, in the ExACT study, only a small proportion (4.4%) of 12 
participants had positive D-dimers whilst on anticoagulation. Out of the 38 participants who 13 
went on to develop VTE recurrences, by far the majority (n=33, 87%) had negative D-dimer 14 
results. Therefore, D-dimer results using a standard cut off, on anticoagulated patients are 15 
not helpful to determine patients at low risk of VTE recurrence to stop anticoagulation. It is 16 
possible that a lower D-dimer cut off threshold could be more informative for patients on 17 
anticoagulation. The HERDOO2 rule has been prospectively validated using a lower cut off 18 
(250mcg/L) and a different D-dimer assay (VIDAS)(Roger et al 2017). However, other 19 
investigators have not used this cut off (e.g. Palareti et al Blood 2014, Kearon C 2015 and 20 
2019). The optimal D-dimer cut off and specific assay to use in this context remains 21 
uncertain. In addition, it is unclear whether single testing or serial testing is better and how 22 
results should influence clinical management (Kearon and Akl 2014).  23 
 24 
The limitations of the ExACT study include that nearly all patients in the extended AT arm 25 
received warfarin treatment whereas DOACs are now the preferred choice for VTE secondary 26 
prevention in the majority of patients. In addition, interpretation of bleeding outcomes and 27 
subgroup analyses (age and sex) are limited due to insufficient patient numbers (including 1/3 28 





In summary, the ExACT study confirms that extended AT treatment for a first unprovoked VTE 1 
provides substantial protection in terms of recurrent VTE but does not reduce risk of PTS or 2 
improve QoL and is associated with a non-significant increase in bleeding. Finally, D-dimer 3 
results, using a standard cut off, in anticoagulated patients are unlikely to inform clinical 4 
decisions.  5 
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